Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study

被引：0
|
作者：
Li Ying
Ji Suyun
Liang Yanhua
Liang Yunsheng
Deng Li
Dang Lin
Lv Chengzhi
Lin Bingjiang
Zhang Furen
Shi Wendi
Li Jinnan
Dong Yu
Dou Guanshen
Yuling Shi
机构：
[1] Tongji University School of Medicine,Department of Dermatology, Shanghai Skin Disease Hospital
[2] Southern Medical University,Department of Dermatology, Dermatology Hospital
[3] Southern Medical University,Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital
[4] Longgang Central Hospital of Shenzhen,Department of Dermatology
[5] Dalian Skin Disease Hospital,Department of Dermatology
[6] Ningbo First Hospital,Department of Dermatology
[7] Shandong First Medical University & Shandong Academy of Medical Sciences,Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology
[8] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Efficacy; Ixekizumab; Psoriasis; Real world; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5464 / 5474
页数：10
相关论文
共 50 条
  • [31] Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
    Gulliver, Wayne
    Gooderham, Melinda J.
    Zhu, Baojin
    Jossart, Christian
    Montmayeur, Sonia
    Burge, Russel
    Reed, Catherine
    DERMATOLOGY AND THERAPY, 2023, 13 (01) : 235 - 244
  • [32] Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis"'
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : E379 - E379
  • [33] Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
    Wayne Gulliver
    Melinda J. Gooderham
    Baojin Zhu
    Christian Jossart
    Sonia Montmayeur
    Russel Burge
    Catherine Reed
    Dermatology and Therapy, 2023, 13 : 235 - 244
  • [34] Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences
    Azhar, Aaminah
    Zaayman, Marcus
    Silfvast-Kaiser, Annika
    Kivelevitch, Dario
    Menter, Alan
    Paek, So Yeon
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [35] Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasis
    Khatri, S.
    Amir, Y.
    Min, M.
    Goldblum, O.
    Solotkin, K.
    Yang, F.
    Ridenour, T.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 74
  • [36] Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
    Syed, Yahiya Y.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (01) : 147 - 158
  • [37] Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
    Yahiya Y. Syed
    American Journal of Clinical Dermatology, 2017, 18 : 147 - 158
  • [38] Ocular manifestations in moderate-to-severe psoriasis in India: A prospective observational study
    Kharolia, Anjali
    Parija, Sucheta
    Moharana, Bruttendu
    Sirka, Chandra Sekhar
    Sahu, Sandip Kumar
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (09) : 3328 - 3332
  • [39] Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study
    Fang Xie
    Rui Wang
    Zi-gang Zhao
    Xian-fu Meng
    Bi-wen Lin
    Jie Yang
    Wen-juan Wang
    Xiang-yu Ding
    Yi Yang
    Hua Zhao
    Cheng-xin Li
    Heng-jin Li
    Yong Zhou
    Current Medical Science, 2017, 37 : 943 - 947
  • [40] Safety and Efficacy of Etanercept Monotherapy for Moderate-to-severe Plaque Psoriasis:A Prospective 12-week Follow-up Study
    解方
    王睿
    赵梓纲
    孟宪芙
    林碧雯
    杨洁
    王文娟
    丁香玉
    杨怡
    赵华
    李承新
    李恒进
    周勇
    Current Medical Science, 2017, 37 (06) : 943 - 947
12345